Compile Data Set for Download or QSAR
Report error Found 36 Enz. Inhib. hit(s) with all data for entry = 2234
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358869(3-(1-Benzofuran-2-yl)-N-[(2S)-1-hydroxy-3-methylbu...)
Affinity DataIC50: 1.30nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358860(N-[3-(dimethylamino)propyl]-3-[4-(morpholin-4-yl)f...)
Affinity DataIC50: 1.5nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358868(3-(1-Benzofuran-2-yl)-N-[2-(dimethylamino)ethyl]im...)
Affinity DataIC50: 1.70nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358856(N-(2-methoxyethyl)-N-methyl-3-[4-(morpholin-4-yl)f...)
Affinity DataIC50: 2.60nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358858(N-[(2R)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...)
Affinity DataIC50: 2.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358861(3-(1-Benzofuran-2-yl)-N-[3-(dimethylamino)propyl]i...)
Affinity DataIC50: 3.30nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358853(N-(3-methoxypropyl)-3-[4-(morpholin-4-yl)furo[3,2-...)
Affinity DataIC50: 3.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358862(3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxypropan-2-yl...)
Affinity DataIC50: 4.10nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358852(N-benzyl-3-[4-(morpholin-4-yl)furo[3,2-c]pyridin-2...)
Affinity DataIC50: 4.40nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358860(N-[3-(dimethylamino)propyl]-3-[4-(morpholin-4-yl)f...)
Affinity DataIC50: 4.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358857(N-(2-methoxyethyl)-3-[4-(morpholin-4-yl)furo[3,2-c...)
Affinity DataIC50: 4.60nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358863(3-(1-Benzofuran-2-yl)-N-(3-methoxypropyl)imidazo[1...)
Affinity DataIC50: 4.90nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358865(3-(1-Benzofuran-2-yl)-N-benzylimidazo[1,2-b]pyrida...)
Affinity DataIC50: 5.20nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358852(N-benzyl-3-[4-(morpholin-4-yl)furo[3,2-c]pyridin-2...)
Affinity DataIC50: 5.60nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358858(N-[(2R)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...)
Affinity DataIC50: 5.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358864(3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxy-3-methylbu...)
Affinity DataIC50: 6.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358853(N-(3-methoxypropyl)-3-[4-(morpholin-4-yl)furo[3,2-...)
Affinity DataIC50: 7nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358859(N-[(2S)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...)
Affinity DataIC50: 7.30nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358861(3-(1-Benzofuran-2-yl)-N-[3-(dimethylamino)propyl]i...)
Affinity DataIC50: 7.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358866(3-(1-Benzofuran-2-yl)-N-(2-methoxyethyl)imidazo[1,...)
Affinity DataIC50: 8nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358856(N-(2-methoxyethyl)-N-methyl-3-[4-(morpholin-4-yl)f...)
Affinity DataIC50: 8.70nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358867(3-(1-Benzofuran-2-yl)-N-benzyl-N-methylimidazo[1,2...)
Affinity DataIC50: 8.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358862(3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxypropan-2-yl...)
Affinity DataIC50: 8.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358863(3-(1-Benzofuran-2-yl)-N-(3-methoxypropyl)imidazo[1...)
Affinity DataIC50: 9.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358865(3-(1-Benzofuran-2-yl)-N-benzylimidazo[1,2-b]pyrida...)
Affinity DataIC50: 12nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358864(3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxy-3-methylbu...)
Affinity DataIC50: 12nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358857(N-(2-methoxyethyl)-3-[4-(morpholin-4-yl)furo[3,2-c...)
Affinity DataIC50: 12nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358866(3-(1-Benzofuran-2-yl)-N-(2-methoxyethyl)imidazo[1,...)
Affinity DataIC50: 15nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358859(N-[(2S)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...)
Affinity DataIC50: 21nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358867(3-(1-Benzofuran-2-yl)-N-benzyl-N-methylimidazo[1,2...)
Affinity DataIC50: 23nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358868(3-(1-Benzofuran-2-yl)-N-[2-(dimethylamino)ethyl]im...)
Affinity DataIC50: 34nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358869(3-(1-Benzofuran-2-yl)-N-[(2S)-1-hydroxy-3-methylbu...)
Affinity DataIC50: 42nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358854(N-[2-(dimethylamino)ethyl]-N-methyl-3-[4-(morpholi...)
Affinity DataIC50: 88nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358855((4-Methylpiperazin-1-yl){3-[4-(morpholin-4-yl)furo...)
Affinity DataIC50: 110nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358854(N-[2-(dimethylamino)ethyl]-N-methyl-3-[4-(morpholi...)
Affinity DataIC50: 140nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM358855((4-Methylpiperazin-1-yl){3-[4-(morpholin-4-yl)furo...)
Affinity DataIC50: 280nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent